192 related articles for article (PubMed ID: 33035598)
41. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis.
Sinha B; Ghosal S
Diabetes Ther; 2019 Jun; 10(3):891-899. PubMed ID: 30875065
[TBL] [Abstract][Full Text] [Related]
42. Heart failure hospitalisation relative to major atherosclerotic events in type 2 diabetes with versus without chronic kidney disease: A meta-analysis of cardiovascular outcomes trials.
Sacre JW; Magliano DJ; Shaw JE
Diabetes Metab; 2021 Sep; 47(5):101249. PubMed ID: 33744399
[TBL] [Abstract][Full Text] [Related]
43. Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin.
Hsu PF; Sung SH; Cheng HM; Shin SJ; Lin KD; Chong K; Yen FS; Yu BH; Huang CT; Hsu CC
J Clin Endocrinol Metab; 2018 Oct; 103(10):3611-3619. PubMed ID: 30113697
[TBL] [Abstract][Full Text] [Related]
44. Impaired Glucose Tolerance or Newly Diagnosed Diabetes Mellitus Diagnosed during Admission Adversely Affects Prognosis after Myocardial Infarction: An Observational Study.
George A; Bhatia RT; Buchanan GL; Whiteside A; Moisey RS; Beer SF; Chattopadhyay S; Sathyapalan T; John J
PLoS One; 2015; 10(11):e0142045. PubMed ID: 26571120
[TBL] [Abstract][Full Text] [Related]
45. International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
Harumi Higuchi Dos Santos M; Sharma A; Sun JL; Pieper K; McMurray JJ; Holman RR; Lopes RD
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28087508
[TBL] [Abstract][Full Text] [Related]
46. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.
Sharma A; Ofstad AP; Ahmad T; Zinman B; Zwiener I; Fitchett D; Wanner C; George JT; Hantel S; Desai N; Mentz RJ
JACC Heart Fail; 2021 Aug; 9(8):568-577. PubMed ID: 34325887
[TBL] [Abstract][Full Text] [Related]
47. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
[TBL] [Abstract][Full Text] [Related]
48. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.
Holman RR; Bethel MA; Chan JC; Chiasson JL; Doran Z; Ge J; Gerstein H; Huo Y; McMurray JJ; Ryden L; Liyanage W; Schröder S; Tendera M; Theodorakis MJ; Tuomilehto J; Yang W; Hu D; Pan C;
Am Heart J; 2014 Jul; 168(1):23-9.e2. PubMed ID: 24952856
[TBL] [Abstract][Full Text] [Related]
49. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.
Toth PP; Schwartz GG; Nicholls SJ; Khan A; Szarek M; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Lebioda K; Wong NCW; Sweeney M; Ray KK;
Am J Prev Cardiol; 2022 Sep; 11():100372. PubMed ID: 36039183
[TBL] [Abstract][Full Text] [Related]
50. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
51. Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated meta-analysis.
Cao Y; Li P; Li Y; Han Y
ESC Heart Fail; 2022 Jun; 9(3):1942-1953. PubMed ID: 35338608
[TBL] [Abstract][Full Text] [Related]
52. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
Mehra MR; Vaduganathan M; Fu M; Ferreira JP; Anker SD; Cleland JGF; Lam CSP; van Veldhuisen DJ; Byra WM; Spiro TE; Deng H; Zannad F; Greenberg B
Eur Heart J; 2019 Nov; 40(44):3593-3602. PubMed ID: 31461239
[TBL] [Abstract][Full Text] [Related]
53. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
[TBL] [Abstract][Full Text] [Related]
54. Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.
Verma S; Bain SC; Buse JB; Idorn T; Rasmussen S; Ørsted DD; Nauck MA
JAMA Cardiol; 2019 Dec; 4(12):1214-1220. PubMed ID: 31721979
[TBL] [Abstract][Full Text] [Related]
55. What does the Acarbose Cardiovascular Evaluation (ACE) trial tell us?
Holman RR
J Diabetes; 2018 Aug; 10(8):683-685. PubMed ID: 29774661
[No Abstract] [Full Text] [Related]
56. Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.
Morrow LM; Becker F; Coleman RL; Gerstein HC; Rydén L; Schöder S; Gray AM; Leal J; Holman RR;
J Diabetes; 2024 Feb; 16(2):e13473. PubMed ID: 37915263
[TBL] [Abstract][Full Text] [Related]
57. Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.
Hanefeld M; Karasik A; Koehler C; Westermeier T; Chiasson JL
Diab Vasc Dis Res; 2009 Jan; 6(1):32-7. PubMed ID: 19156626
[TBL] [Abstract][Full Text] [Related]
58. The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.
Sumner G; Salehian O; Yi Q; Healey J; Mathew J; Al-Merri K; Al-Nemer K; Mann JF; Dagenais G; Lonn E;
J Cardiovasc Electrophysiol; 2009 Jul; 20(7):781-7. PubMed ID: 19298567
[TBL] [Abstract][Full Text] [Related]
59. Patients With Type 2 Diabetes Mellitus and Heart Failure Benefit More From Sodium-Glucose Cotransporter 2 Inhibitor: A Systematic Review and Meta-Analysis.
Chen C; Peng H; Li M; Lu X; Huang M; Zeng Y; Dong G
Front Endocrinol (Lausanne); 2021; 12():664533. PubMed ID: 34759887
[TBL] [Abstract][Full Text] [Related]
60. Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
Wong YW; Thomas L; Sun JL; McMurray JJ; Krum H; Hernandez AF; Rutten GE; Leiter LA; Standl E; Haffner SM; Mazzone T; Martinez FA; Tognoni G; Giles T; Califf RM
Circ Heart Fail; 2013 Mar; 6(2):203-10. PubMed ID: 23388113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
